TGF-β:糖尿病病中的难以捉摸的目标
Priya Rani1, Sindhura Lakshmi Koulmane Laxminarayana2, Shilna Muttickal Swaminathan1
1Department of Nephrology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.
Renal failure
|April 3, 2025
概括
转化生长因子-β (TGF-β) 是纤维化中的关键. 研究探索其在糖尿病病 (DKD) 中的作用,以潜在的诊断和治疗,避免广泛的途径抑制.
科学领域:
- 细胞生物学 细胞生物学
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 转化生长因子-β (TGF-β) 是一个关键的细胞因子,参与许多细胞过程.
- TGF-β家族包括1,2和3等同形式,显著影响纤维化级联.
- 糖尿病病 (DKD) 是一种日益增长的糖尿病并发症,非白性形式为病原发生提供了新的见解.
研究的目的:
- 审查TGF-β作为细胞因子的基本方面.
- 阐明TGF-β在糖尿病病 (DKD) 病理学中的特定作用.
- 提供关于验证TGF-β作为DKD的诊断标记物和治疗点的研究的最新信息.
主要方法:
- 关于基本TGF-β生物学的文献综述.
- 对研究TGF-β参与糖尿病病的研究进行分析.
- 检查研究TGF-β作为诊断和治疗剂的潜力.
主要成果:
- TGF-β在糖尿病脏病的病理学中起着重要作用.
- 血清和尿液中TGF-β的存在表明其作为诊断生物标志物的潜力.
- 调节TGF-β具有潜在的治疗目标,尽管完全封锁可能会产生不良影响.
结论:
- TGF-β在糖尿病病的发展和进展中起着至关重要的作用.
- TGF-β作为DKD管理中的诊断工具和治疗目标具有前景.
- 需要进一步的研究来充分验证TGF-β的候选性,同时考虑广泛信号抑制的潜在风险.
相关概念视频
01:16TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
01:24Glucagon-like Receptor Agonists
276
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
276
01:23Dipeptidyl Peptidase 4 Inhibitors
142
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
142
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K